TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in ...
About DESTINY-Ovarian01 DESTINY-Ovarian01 is a global, multicenter, randomized, open-label, phase 3 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) in combination with bevacizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback